235 related articles for article (PubMed ID: 25806830)
1. Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
Palmerini E; Söderberg S; Mondillo S; Favilli R; Lunghetti S
Acute Card Care; 2015 Mar; 17(1):14-9. PubMed ID: 25806830
[TBL] [Abstract][Full Text] [Related]
2. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
3. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
[TBL] [Abstract][Full Text] [Related]
4. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
[TBL] [Abstract][Full Text] [Related]
5. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
6. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
Sargento L; Brito D; Matias JS; Madeira H
Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
[TBL] [Abstract][Full Text] [Related]
8. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
[TBL] [Abstract][Full Text] [Related]
9. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure.
Ikonomidis I; Parissis JT; Paraskevaidis I; Kourea K; Bistola V; Lekakis J; Filippatos G; Kremastinos DT
Eur J Heart Fail; 2007 Dec; 9(12):1172-7. PubMed ID: 18062901
[TBL] [Abstract][Full Text] [Related]
10. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Feola M; Lombardo E; Taglieri C; Vallauri P; Piccolo S; Valle R
Med Sci Monit; 2011 Feb; 17(3):PI7-13. PubMed ID: 21358614
[TBL] [Abstract][Full Text] [Related]
11. Myocardial efficiency during levosimendan infusion in congestive heart failure.
Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
14. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
[TBL] [Abstract][Full Text] [Related]
15. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
16. Assessment of quality of life using three activity questionnaires in heart failure patients after monthly, intermittent administration of levosimendan during a six-month period.
Papadopoulou EF; Mavrogeni SI; Dritsas A; Cokkinos DV
Hellenic J Cardiol; 2009; 50(4):269-74. PubMed ID: 19622496
[TBL] [Abstract][Full Text] [Related]
17. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
18. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]